Stock comparison
Merck & Co., Inc. is 61.2x more valuable than Travere Therapeutics, Inc. by market capitalization ($371.29 B vs $6.07 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRK is larger
Merck & Co., Inc. is 61.2x more valuable than Travere Therapeutics, Inc. by market capitalization ($371.29 B vs $6.07 B).
Market value leader
MRK
Merck & Co., Inc. is 61.2x more valuable than Travere Therapeutics, Inc. by market capitalization ($371.29 B vs $6.07 B).
Revenue leader
MRK
TVTX: $490.73M vs MRK: $65.01B.
Profit leader
MRK
TVTX: -$25.55M vs MRK: $18.25B.
Margin leader
MRK
TVTX: -5.2% vs MRK: 28.1% net margin.
| Metric | TVTX | MRK |
|---|---|---|
| Market cap | $6.07 B | $371.29 B |
| US-listed rank | #1282 | #34 |
| Revenue (latest FY) | $490.73M | $65.01B |
| Net income (latest FY) | -$25.55M | $18.25B |
| Net margin | -5.2% | 28.1% |
| P/E (trailing FY) | - | 20.3x |
| SEC filings | 1,230 | 998 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Merck & Co., Inc. is 61.2x more valuable than Travere Therapeutics, Inc. by market capitalization ($371.29 B vs $6.07 B).
In their latest fiscal years, Travere Therapeutics, Inc. reported $490.73M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Travere Therapeutics, Inc. and Merck & Co., Inc., or browse the full rankings.